EMA and African Regulators Issue Joint Ebola Vaccine Trial Guidance

EMA's Emergency Task Force and the African Medicines Agency (AMA) published joint guidance on 23 October 2026 for designing and accelerating clinical trials of vaccines against Bundibugyo ebolavirus — the strain behind an outbreak the World Health Organization declared a Public Health Emergency of International Concern on 17 May 2026, centered in the Democratic Republic of the Congo and Uganda. No authorized vaccine currently covers this strain; the guidance sets out what both regulators will expect from sponsors trying to change that while the outbreak is still active.

Why Bundibugyo needs its own guidance

Most Ebola outbreaks since 2014, and the vaccines authorized to fight them — including rVSV-ZEBOV (Ervebo) and the Zabdeno/Mvabea regimen — target Zaire ebolavirus. The outbreak driving this guidance is caused by Bundibugyo ebolavirus, a genetically distinct species first identified in 2007, and regulators consider the existing Zaire-targeted countermeasures unlikely to provide meaningful protection against it. That leaves no authorized vaccine or treatment for the strain currently circulating in the Democratic Republic of the Congo and Uganda, which the WHO declared a Public Health Emergency of International Concern on 17 May 2026. The guidance published 23 October 2026 is meant to compress the years-long path from candidate vaccine to authorized product into a timeline that can still matter for the population currently at risk.

What the guidance asks sponsors to do

The joint paper sets recommendations across the development pathway. Early-phase trials should, where possible, run in the African populations most likely to need the vaccine, so that moving into larger efficacy trials does not require re-establishing trial infrastructure in a new region. On the nonclinical side, some preclinical toxicology studies may be abbreviated or waived for vaccine platforms that already meet established safety standards from other indications, but animal immunogenicity testing is still expected, and the agencies recommend non-human-primate challenge studies before trials advance to Phase II/III. On dosing, the guidance favors single-dose regimens over multi-dose schedules, reflecting the practical reality that a population at risk during an active outbreak is easier to protect with one visit than several. For pivotal efficacy trials, the agencies back randomized ring vaccination — vaccinating the contacts of confirmed cases, the design used to establish Ervebo's efficacy during the 2014–2016 West African outbreak — and say a shared platform-trial design can test multiple candidates at once, provided each retains its own protocol, control arm and statistical analysis plan rather than pooling across candidates. The guidance also directs that pregnant women and children be included in trials once sufficient safety data exists from the general adult population, rather than being excluded by default.

The candidates this guidance is written for

Three vaccine platforms have been identified as Bundibugyo candidates: a recombinant vesicular stomatitis virus (rVSV)-based vaccine built on the same vector technology as Ervebo, a ChAdOx1 adenoviral-vector vaccine using the platform behind several COVID-19 vaccines, and an mRNA vaccine. None is yet authorized against this strain, and the guidance does not endorse any one platform — it sets the evidentiary bar each would need to clear, under either regulator, to reach authorization.

What this changes operationally

• Aligned development, not duplicated development: sponsors developing a Bundibugyo vaccine candidate now have one set of expectations that both EMA and the AMA have endorsed, rather than needing to negotiate trial design separately with each regulator during an active public health emergency.
• Faster nonclinical-to-clinical transition: the allowance to abbreviate certain preclinical toxicology work for established platforms — while still requiring animal immunogenicity data and non-human-primate challenge studies — shortens one of the traditional bottlenecks for an outbreak-pathogen vaccine, without eliminating nonclinical evidence entirely.
• Design precedent: the explicit backing for randomized ring vaccination and shared platform trials gives sponsors a regulator-endorsed design template rather than requiring each program to justify its approach to outbreak-response trial design from scratch.
• First AMA-EMA emergency collaboration: this is reported as the first public health emergency in which EMA has worked jointly with the AMA since the AMA's establishment, a precedent regulatory affairs teams tracking EU-Africa regulatory convergence should note for future emergency responses.

What is not yet settled

The guidance is a position paper setting expectations, not a binding regulation, and it does not itself authorize any vaccine. Which sponsors will pursue which candidate under this framework, how quickly any candidate could reach a Phase III ring-vaccination trial, and how national regulators across the affected region will implement the guidance alongside EMA and the AMA are all open questions the paper does not resolve. The full text of the position paper, including any case-count or epidemiological detail behind its recommendations, sits with EMA's and the AMA's own publications rather than in secondary summaries.

Frequently asked questions

What did EMA and the AMA publish, and when?

On 23 October 2026, joint guidance on designing and accelerating clinical trials of vaccines against Bundibugyo ebolavirus, the strain behind an active outbreak in the Democratic Republic of the Congo and Uganda.

Why does a new strain need new guidance?

Existing authorized vaccines target Zaire ebolavirus and are considered unlikely to protect against the genetically distinct Bundibugyo strain, so no authorized vaccine currently covers this outbreak.

What does the guidance recommend?

African-based early-phase trials, abbreviated (not eliminated) preclinical toxicology for established platforms, single-dose regimens where feasible, and randomized ring vaccination for Phase III, with shared platform trials allowed across candidates.

What candidates exist today?

Three vaccine platforms: an rVSV-based vaccine, a ChAdOx1 adenoviral-vector vaccine, and an mRNA vaccine — none yet authorized against this strain.